A PHASE-II STUDY OF RECOMBINANT TUMOR-NECROSIS-FACTOR IN RENAL-CELL CARCINOMA - A STUDY OF THE NATIONAL-CANCER-INSTITUTE-OF-CANADA-CLINICAL-TRIALS-GROUP
A PHASE-II STUDY OF RECOMBINANT TUMOR-NECROSIS-FACTOR IN RENAL-CELL CARCINOMA - A STUDY OF THE NATIONAL-CANCER-INSTITUTE-OF-CANADA-CLINICAL-TRIALS-GROUP
复制标题
DOI：
10.1097/00002371-199201000-00008
复制
发表时间：
1992-01-01
影响因子：
3.9
通讯作者：
WEINERMAN, B
中科院分区：
文献类型：
--
作者：
SKILLINGS, J;WIERZBICKI, R;WEINERMAN, B
加拿大国家癌症研究所（NCI）临床试验组进行了一项II期研究，重组肿瘤坏死因子（rTNF）每天静脉注射，每隔一周5天，用于可测量的转移性肾细胞癌。26名患者中有2名患者的反应持续了100 - 200天。毒性严重，包括僵硬、发热、头痛、疲劳、低血压和局部疼痛。我们的结论是，如上所述，rTNF在肾细胞癌中只有适度的抗肿瘤活性，并产生相当大的毒性。我们不打算进一步研究rTNF在这种疾病中的作用。
The National Cancer Institute (NCI) Canada Clinical Trials Group conducted a phase II study of recombinant tumor necrosis factor (rTNF) given intravenously daily for 5 days every other week, in measurable metastatic renal cell carcinoma. Two of 26 patients responded with responses lasting > 200 days. Toxicity was severe including rigors, fever, headache, fatigue, hypotension, and localized pain. We conclude that rTNF, given as described, has only modest antitumor activity in renal cell carcinoma and produces considerable toxicity. We plan no further studies of rTNF in this disease.